New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
StockStory.org on MSN
The 5 most interesting analyst questions from DexCom’s Q4 earnings call
DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management ...
In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage ...
StockStory.org on MSN
DXCM Q4 deep dive: New product launches and international strategy drive outlook
Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results , with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be around $5.21 billion, ...
Sequel Med Tech and (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results